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Abstract
THR0921 is a novel peroxisome proliferator-activated receptor
gamma (PPARγ) agonist with potent anti-diabetic properties.
Because of the proposed role of PPARγ in inflammation, we
investigated the potential of orally active THR0921 to inhibit the
pathogenesis of collagen-induced arthritis (CIA). CIA was
induced in DBA/1J mice by the injection of bovine type II
collagen in complete Freund's adjuvant on days 0 and 21. Mice
were treated with THR0921 (50 mg/kg/day) starting on the day
of the booster injection and throughout the remaining study
period. Both clinical disease activity scores as well as
histological scores of joint destruction were significantly
reduced in mice treated with THR0921 compared to untreated
mice. Proliferation of isolated spleen cells, as well as circulating
levels of IgG antibody to type II collagen, was decreased by
THR0921. Moreover, spleen cell production of IFN-γ, tumor
necrosis factor (TNF)-α and IL-1β in response to exposure to
lipopolysaccharide or type II collagen was reduced by in vivo
treatment with THR0921. Steady state mRNA levels of TNF-α,
IL-1β, monocyte chemotactic protein-1 and receptor activator of
nuclear factor κB ligand (RANKL) in isolated joints were all
decreased in mice treated with THR0921. Finally, THR0921
inhibited osteoclast differentiation of bone marrow-derived cells
stimulated with macrophage colony-stimulating factor and
RANKL. In conclusion, THR0921 attenuates collagen-induced
arthritis in part by reducing the immune response. As such,
PPARγ may be an important therapeutic target for rheumatoid
arthritis.
Introduction
Rheumatoid arthritis (RA) is characterized by a chronic Th-1
associated inflammatory process resulting in systemic immu-
nological abnormalities and progressive joint destruction.
Although the precise etiology and underlying mechanisms of
RA remain to be elucidated, several mediators, and thus
potential therapeutic targets, have emerged. Proinflammatory
cytokines such as tumor necrosis factor (TNF)-α and IL-1β
play a key role affecting the imbalance between Th1 and Th2
cells, as well as the activation of other cytokines, chemokines
and proteinases [1-5]. In addition, recent evidence indicates
that osteoclasts may participate in joint destruction in both ani-
mal models of RA and human disease [6,7]. Receptor activator
of nuclear factor κB ligand (RANKL) has been reported to be
a potent regulator of osteoclast differentiation and activation
[8-11]. Recent biological therapies against TNF-α and IL-1β
have demonstrated promising effects protecting against pro-
gressive joint destruction [12-15]. The clinical use of these
therapies has been limited, however, due to several issues,
including safety and cost of treatment.
Peroxisome proliferator-activated receptor (PPAR)γ is a mem-
ber of the ligand-activated transcription factors in the nuclear
receptor superfamily and was initially characterized as a key
regulator of adipocyte differentiation and lipid metabolism
[16,17]. Recent studies have demonstrated that PPARγ ago-
nists prove to have anti-inflammatory and immunomodulatory
therapeutic effects [2]. Indeed, the natural PPARγ ligand 15-
deoxy-Delta (12,14)-prostaglandin J2 as well as synthetic
PPARγ agonists such as rosiglitazone and troglitazone havePage 1 of 8
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However, the mechanisms for the beneficial effects of PPARγ
agonists in arthritis have not been fully delineated. THR0921
is an orally active PPARγ agonist with potent anti-diabetic
effects. Its main structural components consist of a thiazolidin-
edione (TZD) ring covalently linked to a polyphenolic back-
bone, based on compounds derived from the bark of plants of
the Pterocarpus genus. Plant extracts from this origin have
long been used in the Indian Ayurvedic system of medicine
[20,21]. Given the potential role of PPARγ in inflammatory
processes, we hypothesized that THR0921 may have protec-
tive effects in a murine model of RA. Collagen-induced arthritis
(CIA) is a widely used experimental polyarthritis model that has
many common histopathological features with human RA.
Using this model, we observed marked therapeutic effects of
THR0921 upon joint destruction. In addition, we demonstrate
that the benefit of THR0921 is due, in part, to inhibitory effects




Female DBA/1J mice (six weeks old) were obtained from the
Jackson Laboratory (Bar Harbor, ME, USA). All mice were
maintained in a room equipped with an air-filtering system, and
the cages and water were sterilized. All procedures performed
were in compliance with the Animal Welfare Act and US
Department of Agriculture regulations and were approved by
Stanford University Animal Care and Use Committee.
Collagen-induced arthritis
CIA was induced as previously reported [22]. Briefly, six-week
old female DBA/1J mice were immunized at the base of the tail
with 200 µg of bovine type II collagen (CII) dissolved in 100 µl
of 0.05 M acetic acid and mixed with an equal volume (100 µl)
of complete Freund's adjuvant (Chondrex Inc., Redmond, WA,
USA). On day 21, the mice received a booster injection in the
tail of the same volume.
Experimental protocol
Mice were fed normal chow diet throughout the experimental
period. Starting on day 21, a subset of animals was treated
with THR0921 (50 mg/kg/day; a generous gift from Dr Cole-
man Gross, Theracos, Sunnyvale, CA, USA) mixed in with the
chow. Animals were sacrificed on day 42 by anesthesia with
2, 2, 2-tribromoethanol and cervical dislocation. Serum sam-
ples were collected by intracardiac puncture while tissues
were isolated as outlined below.
Evaluation of development of arthritis
Disease activity of the CIA was assessed every other day
between days 21 and 42 by two blinded observers using a
three-point scale for each paw: 0, normal joint; 1, slight inflam-
mation and redness; 2, severe erythema and swelling affecting
the entire paw, with inhibition of use; and 3, deformed paw or
joint, with ankylosis, joint rigidity, and loss of function. The total
score for clinical disease activity was based on all four paws,
with a maximum score of 12 for each mouse [23].
Histological studies
Hind paws were harvested from all mice on day 42 and fixed
in 4% paraformaldehyde, decalcified with EDTA, and embed-
ded in paraffin; 4 µm sections were prepared. The extent of
arthritis was assessed on sections stained with hematoxylin
and eosin as previously described [24], using the following
scale: 0, normal synovium; 1, synovial membrane hypertrophy
and cell infiltrates; 2, pannus and cartilage erosions, 3, major
erosions of cartilage and subchondral bone; and 4, loss of
joint integrity and ankylosis. The assessment was performed
by two independent investigators who were blinded to the
identity of the specimens, and the average of the two scores
was used.
Proliferation of spleen cells
In vitro proliferation of spleen cells was examined using 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT)
assay as previously described [25]. Spleens were removed on
day 42. Red blood cells were removed by treatment with 0.16
M Tris-NH4Cl solution and cell suspensions (5 × 106 cells/well
in a flat-bottom, 96 well plate) were cultured for 72 h at 37°C
in 5% CO2 in RPMI medium containing 50 µg/ml heat-dena-
tured bovine CII (heated for 10 minutes at 80°C) or 1 µg/ml
phytohemagglutinin (PHA). On the day of the assay, MTT (0.5
mg/ml) was added to the medium in each well, and plates
were returned to the incubator for 1 h. Plates were centrifuged
(500 × g for 10 minutes). Supernatants were removed, and
100 µl of dimethyl sulphoxide were added. The plates were
agitated in the dark for 10 minutes to dissolve the MTT forma-
zan crystals. The absorbance of the samples was then
recorded at 570 nm with background subtracted at 630 nm.
Three wells were analyzed for each condition. Data are pre-
sented as the percentage of the cells cultured with medium
alone. The results are displayed as the mean ± standard error
of the mean (SEM) of three separate experiments.
Enzyme-linked immunosorbant assay quantification of 
auto-antibody production
Serum levels of anti-mouse CII IgG were assayed using a
mouse IgG anti-CII antibody (Ab) assay enzyme-linked immu-
nosorbent assay (ELISA) kit (Chondrex Inc.) on samples
derived on day 42. A standard curve was produced using an
anti-CII Ab provided with the ELISA kit.
Cytokine production by cultured spleen cells
Spleens obtained on day 42 were used for measurements of
in vitro cytokine production. After removal of red blood cells by
treatment with 0.16 M Tris-NH4Cl solution, suspensions of
spleen cells (2 × 106 cells/well) were incubated for 48 h at
37°C and 5% CO2 in supplemented RPMI medium alone, with
50 µg/ml heat-denatured bovine CII, or with 5 µg/mlPage 2 of 8
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(Sigma, St Louis, MO, USA). After a 48 h incubation, the
supernatants were collected and TNF-α, IL-1β, IL-4, IL-10 and
IFN-γ levels were measured using commercially available
sandwich ELISAs (Quantikine Mouse ELISA kit, R&D Systems
Inc., Minneapolis, MN, USA) according to the manufacturer's
protocol.
Quantitative real-time PCR of joint samples
Total RNA was extracted from hind paws using TRIzol (Life
Technologies, Gaithersburg, MD, USA) and RNAeasy kit (Qia-
gen, Valencia, CA, USA) according to the manufacturers'
instructions. Gene expression was determined by analysis of
RNA derived from single hind paws of five representative ani-
mals from each experimental group. After DNase treatment,
cDNA was synthesized from 5 mg of total RNA using MMLV
reverse transcriptase (SuperScript II kit, Invitrogen, Carlsbad,
CA, USA). Amplification was carried out in triplicate at 50°C
for 2 minutes and 95°C for 10 minutes followed by 40 cycles
of 95°C for 15 s and 60°C for 1 minute. A threshold cycle (CT
value) was obtained from each amplification curve using soft-
ware (Applied Biosystems). Data were expressed as fold
changes relative to healthy donor controls using the ∆∆CT
method as described in the manufacturer's guidelines
(Applied Biosystems). A ∆CT value was first calculated by sub-
tracting the CT value for 18S ribosomal RNA from the CT value
for each sample. A ∆∆CT value was then calculated by sub-
tracting the ∆CT value of the control from each group. Fold
changes compared with the control were then determined by
raising 2 to the ∆∆CT power. The primer pairs used in this
study were as follows: for TNF-α, forward 5'-GCCTCTTCT-
CATTCCTGCTT-3', reverse 5'-CACTTGGTGGTTT-
GCTACGA-3'; for IL-1β, forward 5'-
CCCAAGCAATACCCAAAGAA-3', reverse 5'-CATCAGAG-
GCAAGGAGGAAA-3'; for monocyte chemoattractant pro-
tein-1 (MCP-1), forward 5'-AGCCAGATGCAGTTAACGC-3',
reverse 5'-CTGATCTCATTTGGTTCGGA-3'; for RANKL, for-
ward 5'-GCTCCGAGCTGGTGAAGAAAT-3', reverse 5'-
CCCAAAGTACGTCGCATCTTG-3'.
Osteoclast differentiation assay
To investigate the effect of THR0921 on osteoclast formation,
osteoclast differentiation induced by macrophage colony-stim-
ulating factor (M-CSF, Pepro Tech EC, London, UK) and solu-
ble RANKL (sRANKL, Pepro Tech EC) was monitored using a
modified method reported previously [26]. Bone marrow cells
were prepared from the femur and tibia of 6-week-old DBA1/
J mice and incubated in tissue culture dishes (100 mm dishes)
at 37°C in 5% CO2 in the presence of recombinant mouse M-
CSF (100 ng/ml). After 24 h in culture, the non-adherent cells
were collected. The cells were cultured in a 2-well Lab-Tek™
chamber slide (Nalge Nunc International, Rochester, NY,
USA) for 7 days with or without THR0921 (10, 50, and 100
nM) in the presence of RANKL (100 ng/ml), M-CSF (20 ng/
ml), and activin A (10 ng/ml) in Dulbecco's modified Eagle's
medium containing 10% v/v heat-inactivated fetal bovine
serum at 37°C in 5% CO2. Cells were fixed and stained for tar-
trate-resistant acid phosphatase (TRAP; a marker enzyme of
osteoclasts) using a TRAP staining kit (Hokudo, Sapporo,
Japan) [27]. TRAP-positive multinucleated cells containing
more than three nuclei were counted under microscopic exam-
ination (40× magnification) from four randomly selected fields
in each chamber as previously described [28].
Statistical analysis
The results are expressed as the mean ± SEM. Clinical scores
were analyzed by repeated measures analysis of variance with
the Sheffe post-hoc test. The Mann-Whitney U test was used
for all other statistical analyses. A p value of less than 0.05 was
considered significant.
Results
Effect of treatment with THR0921 in mice with collagen-
induced arthritis
The incidence of onset of arthritis was 100% in untreated and
THR0921-treated CIA groups. Repeated measure analysis of
variance demonstrated that THR0921 delayed the onset of
arthritis as well as significantly reducing the clinical disease
activity score during the course of the experiment compared
with CIA mice (Figure 1). From day 28 on, the clinical disease
activity score significantly diverged (p < 0.001), resulting in a
score of 10.3 ± 0.3 and 4.7 ± 2.3 on day 42 in the CIA and
the THR0921-treated groups, respectively. The histology of
ankle joints from CIA mice showed severe proliferation of syn-
ovium with significant inflammatory cell infiltration, pannus
invasion, cartilage damage and bone resorption (Figure 2b)
compared with normal mice (Figure 2a), while joints from
THR0921-treated mice showed mild synovial hyperplasia with
less inflammatory cell infiltration, no pannus formation, and lit-
tle cartilage and bone damage (Figure 2c). The average histo-
logical score on day 42 in CIA and THR0921 mice was 3.3 ±
0.8231 and 4 ± 0.516, respectively (p = 0.0005; Figure 2d).
Decreased spleen cell proliferation after treatment with 
THR0921
To determine whether treatment with THR0921 in vivo is
associated with a cell-mediated immunity to collagen, in vitro
spleen cell proliferation was measured. There was no signifi-
cant difference in the values for phytohemagglutinin-stimu-
lated proliferation in spleen cells obtained from healthy
controls, CIA and THR0921 mice (data not shown). On the
other hand, there was a significant reduction in CII-stimulated
proliferation in spleen cells obtained from THR0921-treated
mice compared with CIA mice without treatment (p < 0.001;
Figure 3a). However, CII-stimulated proliferation of spleen
cells derived from THR0921 mice was not completely
reduced to the level of that from healthy DBA control mice.
To determine whether treatment with THR0921 in vivo is
associated with a reduction of CII Ab production, serum wasPage 3 of 8
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ELISA assay. The anti-CII IgG Ab levels in the serum of
THR0921-treated CIA mice were significantly lower than
those in untreated CIA mice (p = 0.0002; Figure 3b).
As inflammatory cytokines are thought to play a critical role in
the pathogenesis of RA, we monitored the production of the
proinfammatory cytokines TNF-α, IL-1β, and INF-γ as well as
anti-inflammatory IL-4 and IL-10 in the spleen cell superna-
tants by ELISA. In vivo treatment with THR0921 resulted in
reduced production of TNF-α, IL-1β, and INF-γ by spleen cells
cultured for 48 h with either LPS or CII compared with cells
from vehicle-treated CIA mice (Figure 4). On the other hand,
no difference was observed in elaborated levels of IL-4 and IL-
10 between spleen cells derived from any of the groups (data
not shown).
Cytokine expression in ankle joints
To investigate the effect of oral administration of THR0921 at
the site of joint destruction, the expression levels of TNF-α, IL-
1β, MCP-1 and RANKL mRNA were examined by real-time
RT-PCR analysis. As expected, expression of each of these
cytokines was significantly increased with CIA (p < 0.001);
treatment with THR0921 reduced cytokine levels nearly to
control levels (p < 0.01; Figure 5).
Inhibitory effect of THR0921 on osteoclast 
differentiation of bone marrow cells induced by M-CSF 
and RANKL in vitro
As osteoclasts play an important role in bone destruction of
inflamed joints, we investigated the effect of THR0921 on
osteoclast differentiation of bone marrow-derived cells. M-
CSF and sRANKL induced differentiation of bone marrow
cells derived from normal and arthritic mice was monitored by
TRAP-positive multinucleated cell formation; this effect was
dose-dependently reduced with THR0921 treatment. Similar
effects were observed when osteoclastogenesis was stimu-
lated with RANKL (p < 0.001 for 10-7 M, and 10-8 M of
THR0921 compared with no THR0921; Figure 6).
Discussion
In this study, oral administration of THR0921 resulted in
marked reduction in inflammatory severity as well as
histological degree of CIA without any obvious adverse
effects. Although the prophylactic study design limits immedi-
ate clinical translation, the results indicate an important regu-
latory role for PPARγ and suggest further study is warranted.
Figure 1
Clinical disease activity of collagen-induced arthritis (CIA). DBA/1J 
mice were immunized with type II collagen and complete Freund's adju-
vant (CFA) on days 0 and 21. The mice were then supplemented with 
THR0921 (50 mg/kg; open circles) or vehicle (closed circles) for 3 
weeks. The clinical disease activity of CIA was determined every other 
day using a three-point scale for each paw. Data are expressed as 
mean ± standard error of the mean (n = 10/group; asterisks indicate p 
< 0.001 versus untreated-CIA mice).
Figure 2
Histological analysis of the hindpaws. (a) Representative haematoxylin 
and eosin stained section from a control mouse shows normal cartilage 
and absence of infiltrate in the synovium. (b) Section from mouse with 
collagen-induced arthritis (CIA) indicates marked infiltration of leuko-
cytes along with disruption and loss of articular cartilage. (c) Section 
from THR0921 treated CIA mouse showing nearly intact articular carti-
lage and subchondral bone, and less synovial hyperplasia. (d) Mean ± 
standard error of the mean of histological scores (n = 10/group; aster-
isks indicate p < 0.001).Page 4 of 8
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clear that the disease process is characterized by infiltration of
leukocytes and erosion of cartilage and bone. Recent studies
have indicated that many of the cells involved with RA, namely
mononuclear leukocytes [29], articular cartilage and chondro-
Figure 3
Effects on spleen cell proliferation and CII Ab production. (a) Spleen 
cell proliferation. Spleen cells were isolated from mice on day 42, stim-
ulated with type II collagen (CII) (50 µg/ml) and cultured for 72 h. Cell 
number was measured by a 3-[4,5-dimethylthiazol-2-yl]-2,5-diphe-
nyltetrazolium bromide (MTT) assay and expressed as percentage of 
cells derived from control animals. Histograms represent mean ± stand-
ard error of the mean (n = 5/group; the asterisk indicates p < 0.001 
versus control; the hash symbol indicates p < 0.01 versus collagen-
induced arthritis (CIA) mice without treatment. (b) Serum anti-CII anti-
body (Ab) levels. Ab concentrations in the serum (day 42) were meas-
ured by enzyme-linked immunosorbant assay. Histograms represent the 
mean ± standard error of the mean (n = 10/group; the asterisk indi-
cates p < 0.001 versus control; the hash symbol indicates p < 0.01 
versus CIA mice without treatment).
Figure 4
Cytokine production by spleen cells. Spleens were obtained from con-
trol DBA/1J (Control) collagen-induced arthritis (CIA) mice, and 
THR0921 treated mice at day 42 and single cell suspensions were cul-
tured with medium alone, 50 µg/ml type II collagen, or 5 mg/ml lipopol-
ysaccharide (LPS) for 48 h. The levels of INF-γ, IL-1β, and tumor 
necrosis factor (TNF)-α were measured in supernatants using a spe-
cific enzyme-linked immunosorbant assay. Histograms represent the 
mean ± standard error of the mean (n = 10/group; the hash symbol 
indicates p < 0.01 from control; the dagger symbol indicates p < 0.05 
versus CIA; asterisks indicate p < 0.01 versus CIA).Page 5 of 8
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several potential mechanisms by which THR0921 can protect
against CIA. Previous reports have highlighted the participa-
tion of locally produced cytokines in the inflammation as well
as tissue destruction, even in the early phases of experimental
arthritis [31-33]. We observed that oral administration of
THR0921 resulted in reduced concentrations of
proinflammatory cytokines at both the local and systemic lev-
els. Of particular interest, THR0921 suppressed levels of
MCP-1, a chemokine responsible for monocyte recruitment
and activation. Consistent with these results are previous
observations indicating that PPARγ agonists can inhibit activa-
tion of monocyte/macrophages [34]. As macrophages initiate
the inflammatory process and are the source of many
cytokines responsible for cartilage and bone loss, this may be
a primary mechanism by which THR0921 provides clinical
benefit. The effect of THR0921 and other PPARγ ligands may
be due to their ability to inhibit the activity of key transcription
factors such as activator protein-1 (AP-1) and nuclear factor
κB [35,36]. As such, targeted therapy against nuclear factor
κB activation has proven successful in experimental arthritis
models [35,36].
In addition to stimulated macrophages in the affected joints,
the pathogenesis of CIA is also dependent upon T-cell activa-
tion [37]. Prior studies have shown that T-cells are involved
with the initiation of synovial hyperplasia, an early step leading
to bone destruction. In addition, T-cell infiltrate is directly cor-
related to severity of arthritis. As such, our observation that
THR0921 reduced CII-induced spleen cell proliferation may
indicate a major mode of protection in this model. Indeed, as a
PPARγ agonist, THR0921 may be expected to alter T-cell
function. Clark et al. [38] demonstrated that PPARγ ligands
significantly blocked the proliferative response of both T-cell
clones and freshly isolated splenocytes. In addition, we
observed reduced circulating levels of CII Ab in THR0921
treated animals, thereby providing less of a stimulus for an
immune response [39,40]. A potential drawback of the current
findings, however, is that we have not clearly demonstrated a
change in spleen cell population (for example, T-cell content)
by THR0921 treatment. Thus, we cannot conclude that the
protective effect was due to reduced T-cell number.
Less controversial, however, are the observed effects upon
spleen cell activation. Chronic treatment with THR0921
resulted in reduced production of TNF-α, IL-1β, and INF-γ from
isolated spleen cells induced by LPS. As the involvement of
each of these cytokines in the pathogenesis of arthritis is well
Figure 5
Steady state mRNA levels of the inflammatory cytokines IL-1β, mono-cyte chemotactic protein (MCP)-1, receptor activator of nuclear factor κB ligand (RANKL) and tumor necrosis f ctor (TNF)-α
cyte chemotactic protein (MCP)-1, receptor activator of nuclear factor 
κB ligand (RANKL) and tumor necrosis factor (TNF)-α. Joints were iso-
lated from mice on day 42, and total RNA was extracted. Cytokine gene 
expression was determined by real time PCR using the ∆∆CT method 
and is expressed as a percent of control (n = 5/group; the hash symbol 
indicates p < 0.01 from control; the dagger symbol indicates p < 0.05 
versus untreated collagen-induced arthritis (CIA)).
Figure 6
Effect of THR0921 on osteoclast differentiation. Mouse bone marrow 
cells were incubated for 8 days in the presence or absence of macro-
phage colony-stimulating factor (M-CSF; 10 ng/ml), soluble receptor 
activator of nuclear factor κB ligand (sRANKL; 30 ng/ml), and 
THR0921 at the concentrations shown. After incubation, cells were 
stained with the tartrate-resistant acid phosphatase (TRAP) staining kit 
and enumerated under 40× magnification. The mean ± standard error 
of the mean of TRAP-positive multinuclear cells containing three or 
more nuclei from four randomly selected fields is shown. The hash sym-
bol indicates p < 0.01; the dagger symbol indicates p < 0.05 versus 
cells stimulated with M-CSF + sRANKL without THR0921.Page 6 of 8
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disease development. On the other hand, we did not observe
any effects upon the levels of the anti-inflammatory cytokines
IL-4 and IL-10. These results suggest that the major effect of
THR0921 is to suppress proinflammatory mechanisms as
opposed to activating counter-regulatory gene transcription.
Suppression of osteoclast formation and activation has
emerged as a pivotal therapeutic strategy used against joint
destruction in arthritis. In the current study, THR0921 clearly
inhibited the differentiation and maturation of osteoclast-like
cells induced by sRANKL and M-CSF in the mouse bone mar-
row culture assay in a dose dependent manner. Of note,
THR0921 almost completely inhibited the osteoclastogenesis
in vitro at a concentration equivalent to serum levels achieved
in mice (for example, 10-6 M; data not shown). These data sug-
gest that THR0921 may directly act on the lineage of macro-
phages/monocytes that differentiate into bone-resorbing
osteoclasts. The use of sRANKL as a stimulus is supported by
recent studies implicating it as an essential regulator of osteo-
clast recruitment and differentiation, as well as its crucial role
in rheumatoid joint destruction [9]. It is, therefore, intriguing
that THR0921 had the additional effect of reducing local
expression of RANKL in affected joints.
THR0921 has a spectrum of activity that differs from other
commercially available thiazolidinediones (TZDs). It is impor-
tant to note that the anti-inflammatory effects observed with
THR0921 in the current study were achieved with a dose that
was 10 times less than that used for troglitazone in a similar
model of arthritis [2]. This is particularly surprising because
THR0921 is a weak activator of PPARγ compared to rosiglita-
zone and has less adipogenic activity. This may also be advan-
tageous, however, when considering other side effects of TZD
treatment. For example, THR0921 is expected to produce less
weight gain than current commercially available PPARγ activa-
tors. Moreover, THR0921 would be expected to produce less
edema, an important consideration in arthritis therapy. Further-
more, the oral formulation of THR0921 would provide greater
safety and convenience over current anti-cytokine therapies
that are delivered by injection.
Conclusion
We demonstrate that oral administration of THR0921 potently
attenuates the development of progressive joint destruction in
mice with CIA. This effect is due, in part, to its ability to inhibit
T-cell proliferation, reduce proinflammatory cytokine produc-
tion, and suppress osteoclastic bone resorption. The findings
in this study suggest that THR0921 may be developed into a
potential therapeutic agent for arthritis.
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